Yposkesi, an SK pharmteco company, is one of Europe’s largest Contract Development and Manufacturing Organizations (CDMO) for cell and gene therapy viral vector manufacturing. As a trusted partner for biotechs and pharma seeking to advance clinical trials and commercialize new Advanced Therapy Medicinal Products (ATMPs), Yposkesi offers a full range of services in lentiviral vectors & AAV (Adeno-Associated Virus) cGMP manufacturing.
The Yposkesi story begins in 1990 with the AFM-Telethon, the French Muscular Dystrophy Association, and a mission to make innovative therapies accessible to patients with genetic disorders and other disabilities. After years of genome research and human clinical trials, the association decided to develop a viral vector manufacturing facility to accelerate the time to market for gene therapies: Yposkesi was created in 2016. Leveraging this unique expertise and knowledge, Yposkesi become a pioneer in his field. Since March 2021, Yposkesi welcomed SK Inc. as its main shareholder. With this new partnership, Yposkesi becomes a member of SK pharmteco, a global CDMO player with 80 years of experience. With operations including 7 cGMP manufacturing and development facilities across the United States, Korea, Ireland, and France, SK pharmteco is bringing to Yposkesi a global presence with advanced technologies. Since September 2022, the Center for Breakthrough Medicines, Philadelphia-based cell and gene therapy CDMO, is integrated with Yposkesi to establish a global CGT business unit with unprecedented capabilities and capacity.
Located in the Genepole campus in Corbeil-Essonnes (South of Paris) in France, Yposkesi’s current 50,000 sq ft. (approx. 5,000m2) facility operates multiple manufacturing suites for bulk drug substance (up to 1,000L) and Fill & Finish to support the growing demand for late-phase projects.
In order to accelerate the time to market for cell and gene therapies, Yposkesi is currently building a second large-scale facility, designed for EMA and FDA compliance that will increase its global footprint to 100,000 sq ft. (approx. 10,000m2) in 2024. This state-of-the-art extension will path the way toward commercialization and help us meet our client’s timeline and budget.
Viral vector manufacturing in one of Europe’s largest facilities
Being a pioneer in his field, Yposkesi is one of Europe’s largest AAV and lentiviral vector production facilities. With our facilities expanding by 2024, this will further be strengthening Yposkesi’s lead.
We know that time is of the essence in the clinical development of new therapies, and manufacturing is often a bottleneck for gene therapy manufacturers. The sheer size of our cGMP facility, dedicated technical team, and expertise enable us to readily accommodate new projects and meet the on-time demands of our clients breaking ground in therapeutic treatments.